MEDIBANK PRIVATE LIMITED (MPL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MPL - MEDIBANK PRIVATE LIMITED

FNArena Sector : Insurance
Year End: June
GICS Industry Group : Insurance
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Medibank Private is the largest Australian private health insurance provider. Previously an Australian Government business enterprise, established by the Whitlam government in 1975, it was privatised in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.47

21 Oct
2021

0.040

OPEN

$3.45

1.17%

HIGH

$3.49

7,279,980

LOW

$3.42

TARGET
$3.504 1.0% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AMP . IAG . ISU . NHF . QBE . SDF . SUN . TWR . CVW . GDG . PSI . FCL .
FNARENA'S MARKET CONSENSUS FORECASTS
MPL: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx 16.0 15.7 xxx
DPS (cps) xxx 12.7 12.8 xxx
EPS Growth xxx 40.0% - 1.9% xxx
DPS Growth xxx 5.8% 0.7% xxx
PE Ratio xxx N/A 22.1 xxx
Dividend Yield xxx N/A 3.7% xxx
Div Pay Ratio(%) xxx 79.3% 81.4% xxx

Dividend yield today if purchased 3 years ago: 4.57%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.65

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/09 - ex-div 6.9c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx16.0
DPS All xxxxxxxxxxxxxxx12.7
Sales/Revenue xxxxxxxxxxxxxxx6,984.4 M
Book Value Per Share xxxxxxxxxxxxxxx69.2
Net Operating Cash Flow xxxxxxxxxxxxxxx498.2 M
Net Profit Margin xxxxxxxxxxxxxxx6.32 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx23.72 %
Return on Invested Capital xxxxxxxxxxxxxxx22.82 %
Return on Assets xxxxxxxxxxxxxxx11.48 %
Return on Equity xxxxxxxxxxxxxxx23.72 %
Return on Total Capital xxxxxxxxxxxxxxx32.71 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx154.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

26/08/2021

3

Neutral

$3.50

0.86%

Operating profit beat UBS estimates in FY21. The health insurance result was partially offset by a weaker second half along with higher corporate costs, and the company's strategy to give back savings should mean customer retention remains strong.

Moreover, UBS assesses productivity benefits are constructive for net margins. Given the clean result compared with peers, UBS now believes the 22.8x PE is justified and prefers Medibank Private heading into the premium round.

Neutral maintained. Target rises to $3.50 from $3.25.

FORECAST
UBS forecasts a full year FY22 dividend of 12.00 cents and EPS of 15.00 cents.
UBS forecasts a full year FY23 dividend of 13.00 cents and EPS of 16.00 cents.

Credit Suisse

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

MPL STOCK CHART

FNArena News on MPL

1
Australian Broker Call *Extra* Edition – Sep 28, 2021

Sep 28 2021 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 27, 2021

Sep 27 2021 - Daily Market Reports
3
Rudi’s View: It’s The End Of The Trend

Sep 02 2021 - Rudi's View
4
FNArena Corporate Results Monitor – 26-08-2021

Aug 26 2021 - Australia
5
Rudi’s View: Early Days, But Plenty Of Signs

Aug 12 2021 - Rudi's View

Latest Insurance News

1
Growth Returns For Suncorp

Aug 10 2021 - Australia
2
Treasure Chest: IAG Re-Rating?

Jun 28 2021 - Treasure Chest
3
Insurers Grapple With Costs And Competition

Jun 16 2021 - Australia
4
Nib Holdings May Need To Tread Carefully

Apr 27 2021 - Australia
5
Insurers Tackle More Risk As NSW Floods

Mar 23 2021 - Australia
6
Suncorp Homes In On Improved Returns

Feb 10 2021 - Australia
7
Reinsurance Key To Insurer Pandemic Claims

Sep 16 2020 - Australia
8
Suncorp Takes Stock Of Risk

Jul 02 2020 - Australia
9
Medibank Private Deflects Talk Of Windfall

May 07 2020 - Australia
10
Steadfast Moves To Reassure

Apr 27 2020 - Australia